CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
|Videos|October 19, 2021
- MHE October 2021
- Volume 31
- Issue 10
Rachel Kotok Goldberg Shares Developing Evidence-Based Behavioral Health Programs for Horizon Has Been a Great Career Accomplishment
Author(s)Briana Contreras
Rachel Goldberg, B.S.N, RN, director of behavioral health client partnerships and product innovation at Horizon Blue Cross Blue Shield of New Jersey, is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video she talks about the career achievement that has given her the greatest satisfaction and who has had the greatest influence on her life.
Advertisement
Articles in this issue
almost 5 years ago
Emerging Health Leaders: Sonia Samagh of Stealth Venturealmost 5 years ago
Emerging Health Leaders: Andrew Toy, M.S., of Clover Healthalmost 5 years ago
Emerging Health Leaders: Evie Powell, Ph.D., of Proprioalmost 5 years ago
Emerging Health Leaders: Michael Palantoni of AthenahealthAdvertisement
Related to this article
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
One of teledentistry's most valuable applications is triage — helping a patient understand whether a concern can wait for an appointment, requires prompt attention or warrants emergency medical care.
Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.
In both mice and human cells, a small molecule selectively blocked the activity of MAP4K4, a protein involved in several major biological pathways.
Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Texas A&M researchers discover promising therapy for fatty liver disease
2
Heather Burrell Ward, M.D., on personalizing TMS in schizophrenia
3
Low birth volume, finances tied to hospital obstetric unit closures
4
The hidden costs of routine radiology and how they can be addressed
5